IDH1 and central nervous system cancer: IDH1 mutations are associated with the aberrant conversion of α-KG to D2HG, an oncogenic metabolite that is recurrent in acute myeloid leukemia, glioma, chondrosarcoma, and intrahepatic cholangiocarcinoma [3, 50–52].